Findings on the test were published in Molecular Psychiatry.
The current system for pain diagnosis and drug prescribing relies on physician evaluations or self-reporting from patients, and this test allows for more precise medicine to guide standards, said study author Alexander Niculescu, MD, PhD.
The test identifies molecules or biomarkers that track pain severity. The information gathered from the test can objectively tell a physician how much pain a patient is experiencing and the amount of medicine they need, cutting down on under- or over-prescribing, Dr. Niculescu said.
Additionally, the molecules identified in the test could help match patients with the drug best suited for them and predict when they may experience pain.
“We can deal with these issues just like you would deal with cardiological issues, or cancer. You would have tests for it, you would have precise medication, and you would have much better outcomes,” Dr. Niculescu said.
More articles on clinical leadership & infection control:
Vaccine hesitancy linked to community norms, researcher says
Pennsylvania health system collaborates with healthcare trust to improve care
Exposure to general anesthesia in early infancy does not affect neurological development
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
